Could a common ADHD drug reawaken motivation?

NCT ID NCT07771595

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This trial explores whether a single dose of atomoxetine, a drug used for ADHD, can enhance motivation and information processing in healthy adults with varying levels of apathy. Participants will complete computer tasks measuring effort, reward, and decision-making after taking either the drug or a placebo. The goal is to see if boosting noradrenaline in the brain can improve the motivational processes that are often impaired in apathy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Atomoxetine (a single 40 mg oral dose)
What this could lead to
If atomoxetine improves motivation-related brain processes, it could point toward a treatment for apathy in people with neuropsychiatric disorders.
What could go wrong
This is a small, early-stage study in healthy volunteers, so results may not apply to patients. Atomoxetine can cause side effects like dry mouth, nausea, or increased heart rate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: 18-45 * Good physical health * Willing and able to give informed consent to participate in the study * Sufficient knowledge of English language to understand and complete the study tasks Exclusion Criteria: * Current DSM-5 axis-I diagnosis (based on SCID results at screening) or history of a severe psychological disorder such as psychotic disorder, bipolar disorder, alcohol or substance abuse, or post-traumatic stress disorder * Previous or current extended period of persistent thoughts about ending one's life (longer than 5 days) or previous suicide attempt * Clinical diagnosis of attention deficit hyperactivity disorder (ADHD) or on the waiting list for assessment * Any intake of CNS-medication in the last 6 weeks (including as part of another study) * Any current intake of blood pressure or other heart medication, including beta blockers * Any current or previous medical condition or medication intake (last month) of any medication that, in the opinion of the study medic, may interfere with the safety of the participant or the scientific integrity of the study. * Severely underweight (BMI \<17) or very obese (BMI \>40), OR otherwise deemed unsuitable for the study due to weight-related concerns at the discretion of the study medic * History of cardiovascular, cerebrovascular disease * Breathing or lung-related illnesses, significant liver or kidney problems, or severe gastrointestinal conditions. * High blood pressure (defined as repeated measurements of blood pressure where either the systolic or the diastolic blood pressure, or both, are at or above 140/90 mmHg (https://doi.org/10.1093/eurheartj/ehy339) * History of recurrent rashes or history of allergic reactions to relevant substances (atomoxetine, placebo treatment) * Significant physical (including visual and auditory) or language impairment that would make complying with the study protocol challenging. * History of palpitations with sudden onset and offset, * History of fainting on exertion or in response to fright or loud noise * Family history of sudden death in a first-degree relative under 40 years of age * Women: pregnancy (as determined by a urine test), breast-feeding * Significant consumption of caffeine (more than about 6 cups of strong coffee per day), nicotine (more than 5 cigarettes per day, or equivalent amount), alcohol (more than two pints of beer a day or equivalent) * Participation in a study that involves the use of medication in the past 3 months * Participation in another study using similar tasks in the past 6 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lethargy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Psychiatry, University of Oxford

    Oxford, OX3 7JX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.